Patients’ and clinicians’ attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis

Therapeutic Advances in Psychopharmacology

Volumn 3, Issue 2, 2013, Pages 89-99

  Kirschner, Matthias ^a   Theodoridou, Anastasia ^a   Fusar Poli, Paolo ^b   Kaiser, Stefan ^a   Jäger, Matthias ^a  

^a UNIVERSITY HOSPITAL OF PSYCHIATRY ZURICH   (Switzerland)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

antipsychotics; attitudes; depot; first episode psychosis; schizophrenia

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE;

ARTICLE; ATTITUDE TO ILLNESS; CHRONIC PATIENT; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CONSULTATION; DRUG FORMULATION; HUMAN; OUTPATIENT CARE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHIATRIST; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; RELAPSE; TREATMENT DURATION;

EID: 84997891835     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125312464106     Document Type: Article

References (48)

1. Alvarez-Jimenez M. Parker A. Hetrick S. McGorry P. Gleeson J. (2011) Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis. Schizophr Bull 37: 619–630.
2. Ascher-Svanum H. Zhu B. Faries D. Salkever D. Slade E. Peng X. et al. (2010) The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry 10: 2.
3. Barnes T. (2011) Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 25: 567–620.
4. Barnes T. Curson D. (1994) Long-term depot antipsychotics. A risk–benefit assessment. Drug Saf 10: 464–479.
5. Barnes T. Shingleton-Smith A. Paton C. (2009) Antipsychotic long-acting injections: Prescribing practice in the UK. Br J Psychiatry 195(Suppl. 52): 37–42.
6. Besenius C. Clark-Carter D. Nolan P. (2010) Health professionals’ attitudes to depot injection antipsychotic medication: a systematic review. J Psychiatr Ment Health Nurs 17: 452–462.
7. Burns T. Fioritti A. Holloway F. Malm U. Rossler W. (2001) Case management and assertive community treatment in Europe. Psychiatr Serv 52: 631–636.
8. Citrome L. (2010) Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. Int J Clin Pract 64: 216–239.
9. Crossley N. Mechelli A. Fusar-Poli P. Broome M. Matthiasson P. Johns L. et al. (2009) Superior temporal lobe dysfunction and frontotemporal dysconnectivity in subjects at risk of psychosis and in first-episode psychosis. Hum Brain Mapp 30: 4129–4137.
10. Davis J. Matalon L. Watanabe M. Blake L. Metalon L. (1994) Depot antipsychotic drugs. Place in therapy. Drugs 47: 741–773.
11. De la Gandara J. Molina L. Rubio G. Rodriguez-Morales A. Borrajo R. Buron J. (2009) Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: The SPHERE study. Expert Rev Neurotherapeut 9: 1463–1474.
12. Emsley R. (2009) New advances in pharmacotherapy for early psychosis. Early Interv Psychiatry 3(Suppl. 1): S8–S12.
13. Emsley R. Oosthuizen P. Koen L. Niehaus D. Medori R. Rabinowitz J. (2008) Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. Int Clin Psychopharmacol 23: 325–331.
14. Fusar-Poli P. Bonoldi I. Yung A. Borgwardt S. Kempton M. Barale F. et al. (2012) Predicting psychosis: a meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry 69(3): 1–10.
15. Fusar-Poli P. Borgwardt S. Crescini A. D’Este G. Kempton M. Lawrie S. et al. (2011a) Neuroanatomy of vulnerability to psychosis: a voxel-based meta-analysis. Neurosci Biobehav Rev 35: 1175–1185.
16. Fusar-Poli P. Howes O. Allen P. Broome M. Valli I. Asselin M. et al. (2010) Abnormal frontostriatal interactions in people with prodromal signs of psychosis: a multimodal imaging study. Arch Gen Psychiatry 67: 683–691.
17. Fusar-Poli P. Howes O. Allen P. Broome M. Valli I. Asselin M. et al. (2011b) Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Mol Psychiatry 16: 67–75
18. Fusar-Poli P. Perez J. Broome M. Borgwardt S. Placentino A. Caverzasi E. et al. (2007) Neurofunctional correlates of vulnerability to psychosis: a systematic review and meta-analysis. Neurosci Biobehav Rev 31: 465–484.
19. Haddad P. Taylor M. Niaz O. (2009) First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: Systematic review of randomised controlled trials and observational studies. Br J Psychiatry 195(Suppl. 52): 20–28.
20. Heres S. Hamann J. Kissling W. Leucht S. (2006) Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry 67: 1948–1953.
21. Heres S. Hamann J. Mendel R. Wickelmaier F. Pajonk F. Leucht S. et al. (2008) Identifying the profile of optimal candidates for antipsychotic depot therapy A cluster analysis. Prog Neuropsychopharmacol Biol Psychiatry 32: 1987–1993.
22. Heres S. Reichhart T. Hamann J. Mendel R. Leucht S. Kissling W. (2011) Psychiatrists’ attitude to antipsychotic depot treatment in patients with first-episode schizophrenia. Eur Psychiatry 26: 297–301.
23. Heyscue B. Levin G. Merrick J. (1998) Compliance with depot antipsychotic medication by patients attending outpatient clinics. Psychiatr Serv 49: 1232–1234.
24. Howes O. Montgomery A. Asselin M. Valli I. Tabraham P. Johns L. et al. (2009) Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry 66: 13–20.
25. Jaeger M. Rossler W. (2010) Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists. Psychiatry Res 175: 58–62.
26. Johnson D. (1984) Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia. J Clin Psychiatry 45(5, Sect. 2): 13–21.
27. Kahn R. Fleischhacker W. Boter H. Davidson M. Vergouwe Y. Keet I. et al. (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371: 1085–1097.
28. Kane J. Aguglia E. Altamura A. Gutierrez J. Brunello N. Fleischhacker W. et al. (1998) Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol 8: 55–66.
29. Kane J. Eerdekens M. Lindenmayer J. Keith S. Lesem M. Karcher K. (2003) Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 160: 1125–1132.
30. Kim B. Lee S. Choi T. Suh S. Kim Y. Lee E. et al. (2008) Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting. Prog Neuro-Psychopharmacol Biol Psychiatry 32: 1231–1235.
31. Lehman A. Lieberman J. Dixon L. McGlashan T. Miller A. Perkins D. et al. (2004) Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 161(2 Suppl.): 1–56.
32. Leucht C. Heres S. Kane J.M. Kissling W. Davis J.M. Leucht S. (2011) Oral versus depot antipsychotic drugs for schizophrenia – a critical systematic review and meta-analysis of randomised long-term trials. Schizophrenia Res 127: 83–92.
33. Lindenmayer J. (2010) Long-acting injectable antipsychotics: focus on olanzapine pamoate. Neuropsychiatr Dis Treat 6: 261–267.
34. Meier J. Becker T. Patel A. Robson D. Schene A. Kikkert M. et al. (2010) Effect of medication-related factors on adherence in people with schizophrenia: a European multi-centre study. Epidemiol Psichiatr Soc 19: 251–259.
35. Nasrallah H. (2007) The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand 115: 260–267.
36. Park M. Han C. Pae C. Lee S. Patkar A. Masand P. et al. (2011) Aripiprazole treatment for patients with schizophrenia: from acute treatment to maintenance treatment. Expert Rev Neurother 11: 1541–1552.
37. Patel M. de Zoysa N. Bernadt M. Bindman J. David A. (2010) Are depot antipsychotics more coercive than tablets? The patient's perspective. J Psychopharmacol 24: 1483–1489.
38. Patel M. Haddad P. Chaudhry I. McLoughlin S. Husain N. David A. (2009) Psychiatrists’ use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years. J Psychopharmacol 24: 1473–1482.
39. Patel M. Nikolaou V. David A. (2003) Psychiatrists’ attitudes to maintenance medication for patients with schizophrenia. Psychol Med 33: 83–89.
40. Robinson D. Woerner M. Alvir J. Bilder R. Goldman R. Geisler S. et al. (1999) Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56: 241–247.
41. Simpson G. (1984) A brief history of depot neuroleptics. J Clin Psychiatry 45(5, Pt 2): 3–4.
42. Smieskova R. Fusar-Poli P. Allen P. Bendfeldt K. Stieglitz R. Drewe J. et al. (2010) Neuroimaging predictors of transition to psychosis – A systematic review and meta-analysis. Neurosci Biobehav Rev 34: 1207–1222.
43. Tiihonen J. Haukka J. Taylor M. Haddad P. Patel M. Korhonen P. (2011) A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 168: 603–609.
44. Waddell L. Taylor M. (2009) Attitudes of patients and mental health staff to antipsychotic long-acting injections: systematic review. Br J Psychiatry 52(Suppl.): S43–S50.
45. Walburn J. Gray R. Gournay K. Quraishi S. David A. (2001) Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 179: 300–307.
46. Weiden P. Schooler N. Weedon J. Elmouchtari A. Sunakawa A. Goldfinger S. (2009) A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. J Clin Psychiatry 70: 1397–1406.
47. Young J. Spitz R. Hillbrand M. Daneri G. (1999) Medication adherence failure in schizophrenia: a forensic review of rates, reasons, treatments, and prospects. J Am Acad Psychiatry Law 27: 426–444.
48. Young J. Zonana H. Shepler L. (1986) Medication noncompliance in schizophrenia: codification and update. Bull Am Acad Psychiatry Law 14: 105–122.